News Quantified

SNGX – soligenix, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Soligenix Details Recent Progress and Upcoming Milestones

Soligenix (NASDAQ:SNGX) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.

SNGX: Positive Results for Phase 2a Trial in Psoriasis [Yahoo! Finance]

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) [Yahoo! Finance]

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

Form SCHEDULE 13G/A SOLIGENIX, INC. Filed by: ARMISTICE CAPITAL, LLC

Form 8-K SOLIGENIX, INC. For: Feb 12

Form 424B5 SOLIGENIX, INC.

Form 8-K SOLIGENIX, INC. For: Jan 23

Form 4 SOLIGENIX, INC. For: Dec 11 Filed by: Donini Oreola

Top News Gainers

1/3 Form 8-K SOLIGENIX, INC. For: Jan 02 26.2%

3/19 Soligenix Announces Positive Top-line Results for its Pivotal Phase 3 FLASH Trial Evaluating SGX301 in Treatment of Cutaneous T-Cell Lymphoma 20.5%

5/14 Form 10-Q SOLIGENIX, INC. For: Mar 31 12.3%

7/26 Form DEF 14A SOLIGENIX, INC. For: Sep 06 12.3%

3/30 Form 10-K SOLIGENIX, INC. For: Dec 31 12.0%

12/13 Form 4 SOLIGENIX, INC. For: Dec 12 Filed by: Donini Oreola 10.9%

7/8 Soligenix Announces Appointment of Diane L. Parks to its Board of Directors 9.5%

10/3 Soligenix to Present at the 20th Annual GCFF Investor Conference in Vancouver, British Columbia, Canada 7.7%

7/10 Form 4 SOLIGENIX, INC. For: Jun 28 Filed by: Pearson Mark E. 7.6%

9/17 Form 8-K SOLIGENIX, INC. For: Sep 16 6.6%

Top News Decliners

3/23 Soligenix and University of Hawai?i at Manoa Initiate Work on Novel Coronavirus Vaccine for COVID-19 -30.0%

4/6 Soligenix Receives European Patent for Therapeutic Use of Synthetic Hypericin to Treat Cutaneous T-Cell Lymphoma -20.0%

4/16 Soligenix Announces Exclusive Licensing Agreement for Novel Vaccine Adjuvant from BTG Specialty Pharmaceuticals -15.8%

4/30 Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma -11.4%

8/29 Soligenix to Present at the RHK Capital 2019 Disruptive Growth Conference -10.1%

3/19 Solgenix up 16% premarket on positive SGX301 data [Seeking Alpha] -10.0%

12/7 Soligenix, Inc. (NASDAQ: SNGX) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. -9.3%

4/20 Soligenix's Upcoming Catalyst For Pipeline Product SGX301 Could Offer A Nice Trade Opportunity [Seeking Alpha] -8.1%

8/13 Form 10-Q SOLIGENIX, INC. For: Jun 30 -8.0%

12/12 Soligenix initiates clinical trial of heat stable ricin toxin vaccine [Seeking Alpha] -7.5%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day